eCite Digital Repository
Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl2 in the blood plasma of colorectal cancer patients
Citation
Ip, V and McKeage, MJ and Thompson, P and Damianovich, D and Findlay, M and Liu, JJ, Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl2 in the blood plasma of colorectal cancer patients, Journal of Analytical Atomic Spectrometry, 23 pp. 881-884. ISSN 0267-9477 (2008) [Refereed Article]
Copyright Statement
Copyright 2008 The Royal Society of Chemistry
DOI: doi:10.1039/b716925f
Abstract
Oxaliplatin is a medically-important platinum-based drug for treating advanced colorectal cancer, but
its clinical pharmacokinetics and biotransformation are not well understood. We report the
development of a reliable sample preparation procedure and a specific HPLC-ICP-MS assay for
oxaliplatin and its putative active biotransformation product Pt(R,R-diaminocyclohexane)Cl2
[Pt(DACH)Cl2], and their application to the analysis of the plasma of patients undergoing a standard 2
h infusion of oxaliplatin. HPLC conditions were identified for separating intact oxaliplatin and
Pt(DACH)Cl2 that were compatible with on-line detection by ICP-MS. Plasma samples were processed
immediately after collection by methanol deproteinization, then stored under conditions in which the
analytes of interest were stable. The linearity of calibration curves (R2 ¼ 0.9974), intra- and inter-assay
accuracy (101–107%) and precision (3.30–7.12%, n ¼ 5), drug recovery (95–108%), and short- and
long-term stability were adequate to quantify oxaliplatin. Clinical application of the assay showed that
intact oxaliplatin was the major active platinum species in the plasma of colorectal cancer patients
given oxaliplatin. Pt(DACH)Cl2 was undetectable in patient samples despite the HPLC-ICP-MS assay
having a limit of detection of 5 nM (1.9 ppb) for this platinum species.
Item Details
Item Type: | Refereed Article |
---|---|
Keywords: | platinum anticancer drug, colorectal cancer, ICP-MS |
Research Division: | Biomedical and Clinical Sciences |
Research Group: | Pharmacology and pharmaceutical sciences |
Research Field: | Clinical pharmacology and therapeutics |
Objective Division: | Health |
Objective Group: | Clinical health |
Objective Field: | Clinical health not elsewhere classified |
UTAS Author: | Liu, JJ (Dr Johnson Liu) |
ID Code: | 89124 |
Year Published: | 2008 |
Web of Science® Times Cited: | 17 |
Deposited By: | Pharmacy |
Deposited On: | 2014-02-25 |
Last Modified: | 2014-08-05 |
Downloads: | 0 |
Repository Staff Only: item control page